Rubius lands $120M bonanza to fund a groundbreaking pipeline effort on a new drug platform
The people at Rubius Therapeutics think they’re on to a game-changing new platform for drug R&D, one that can spawn a wave of transformational new medicines. And they now have one of the biggest venture capital rounds in drug R&D this year to put their dreams to the test in a lineup of new programs now headed for the clinic.
Seeded by Flagship Pioneering and initially backed with a $25 million A round in late 2015, Rubius today is uncorking a $120 million investment “to move a wave of products into the clinic next year,” says Rubius President Torben Straight Nissen. After doubling the staff to 40 over the last 9 months, Rubius will now shoot for 100 over the next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
